Results 31 to 40 of about 1,388,983 (287)

Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial

Nature Communications
Identifying an immunologic marker as a correlate of protection (CoP) for RSV vaccination is important. In the pivotal phase 3 trial, the mRNA-1345 vaccine demonstrated efficacy against RSV in older adults (NCT05127434).
Chong Ma, Jiejun Du, Lan Lan, Archana Kapoor, Gonzalo Perez Marc, Gilberto Jimenez, Christopher J. A. Duncan, Nancy Le Cam, Nina Lin, Frances Priddy, Sanjay Garg, Sonia K. Stoszek, Christine A. Shaw, Jaya Goswami, Eleanor Wilson, Rituparna Das, Honghong Zhou, Lingyi Zheng   +17 more
doaj   +1 more source

Museum Futures: Distributed [PDF]

, 2008
Commissioned as part of Moderna Museet’s 50th anniversary. Museum Futures: Distributed - is a machinima record of the centenary interview with Moderna Museet’s executive Ayan Lindquist in June 2058.
Cummings, Neil, Lewandowska, Marysia
core  

From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function

Advanced Healthcare Materials, EarlyView.
The evolution of lipid nanoparticles (LNPs) spans from RNA‐LNPs, used in mRNA vaccines, to DNA‐LNPs, ideal for gene therapies. Emerging bionano architectures, decorated with DNA and plasma proteins, pave the way for advanced DNA‐based therapies that are more stable, targeted, and customizable.
Erica Quagliarini, Daniela Pozzi, Giulio Caracciolo   +2 more
wiley   +1 more source

High‐Throughput In Vivo Screening Using Barcoded mRNA Identifies Lipid Nanoparticles With Extrahepatic Tropism for In Situ Immunoengineering

Advanced Materials, EarlyView.
A high‐throughput in vivo mRNA LNP screening platform is developed and employed to screen a large library of 122 mRNA LNPs in vivo for delivery to immune, stromal, and parenchymal cells, identifying promising LNP candidates. A novel small particle flow cytometry‐based protein adsorption analysis method is utilized to interrogate protein corona ...
Alex G. Hamilton, Ajay S. Thatte, Junchao Xu, Zhangyi Luo, Hannah C. Safford, Kelsey L. Swingle, Jenna Muscat‐Rivera, Michael Kegel, Xuexiang Han, Ryann A. Joseph, Amanda M. Murray, Hannah C. Geisler, Ricardo C. Whitaker, Lulu Xue, Roman Spektor, Jilian R. Melamed, Drew Weissman, Michael J. Mitchell   +17 more
wiley   +1 more source

Risk factors for severe COVID-19 outcomes in the Asia-Pacific region: a literature review

Frontiers in Public Health
This comprehensive synthesis of severe COVID-19 risk factors specific to the Asia-Pacific (APAC) region addresses gaps in previous global studies, which often overlook regional demographic, epidemiological, and healthcare system variations.
Madeline Thompson, Amanda K. Buttery, Shu Xin Oh, Macy Chan, Byung Hyun Lee, Tomoharu Iino, Yu-Chun Alice Wang, Chris Clarke   +7 more
doaj   +1 more source

A Systemic Selective Modified mRNA Delivery Platform for Preventing Chemotherapy‐Induced Cardiotoxicity

Advanced Science, EarlyView.
In Yoo and Mainkar et al., we present a minimally invasive, CM‐selective modRNA delivery system encapsulated in lipid nanoparticles for intravenous (IV) administration. This platform enables selective cardiac translation of therapeutic modRNA but suppresses expression in off‐target tissues, including tumors.
Jimeen Yoo, Gayatri Mainkar, Matteo Ghiringhelli, Bernardo Gindri Dos Santos, Magdalena M. Żak, Keerat Kaur, Ann Anu Kurian, Matthew Adjmi, Segev Sharon, Eftychia Markopoulou, Lucia Žigová, Daniela Hirsch, Sydney Pessin, Rachel Hanan, Juan Luis Escano Abreu, Niki Brisnovali, Nicole Dubois, Leigh Goedeke, Mengcheng Shen, Lior Zangi   +19 more
wiley   +1 more source

Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States

Infectious Diseases and Therapy
Introduction In September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023–2024 Omicron XBB.1.5-containing mRNA COVID ...
Amanda Wilson, Neloufar Rahai, Ekkehard Beck, Elisha Beebe, Brian Conroy, Daina Esposito, Priya Govil, Hagit Kopel, Tianyi Lu, James Mansi, Morgan A. Marks, Katherine E. Mues, Rohan Shah, Michelle Skornicki, Tianyu Sun, Astra Toyip, Mitra Yousefi, David Martin, Andre B. Araujo   +18 more
doaj   +1 more source

Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1

Antibodies, 2022
Monoclonal antibodies have been used successfully as recombinant protein therapy; however, for HIV, multiple broadly neutralizing antibodies may be necessary.
Elisabeth Narayanan, Samantha Falcone, Sayda M. Elbashir, Husain Attarwala, Kimberly Hassett, Michael S. Seaman, Andrea Carfi, Sunny Himansu   +7 more
doaj   +1 more source

Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline

Advanced Science, EarlyView.
This study designs a novel mRNA‐LNP vaccine targeting VZV glycoprotein E (gE) for herpes zoster via an AI‐assisted pipeline. Validated in mice and rhesus macaques, the mRNA‐LNP vaccine shows strong humoral and cellular immune responses, with CD4+ T‐cell responses more effective and durable than Shingrix, offering a promising prophylactic option ...
Kai Dong, Fang Liu, Dawei Wang, Yanfen Li, Man Zhang, Yuting Zhou, Gengshen Song   +6 more
wiley   +1 more source

Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults

Infectious Diseases and Therapy
Introduction Recent data have shown elevated infection rates in several subpopulations at risk of SARS-CoV-2 infection and COVID-19, including immunocompromised (IC) individuals.
Tianyu Sun, Linwei Li, Katherine E. Mues, Mihaela V. Georgieva, Brenna Kirk, James A. Mansi, Nicolas Van de Velde, Ekkehard C. Beck   +7 more
doaj   +1 more source